4DMedical Ltd (AU:4DX) has released an update.
4DMedical Limited, a medical technology company specializing in lung health innovations, has reported the expiry of over two million employee stock options, including a significant portion held by CEO Dr. Andreas Fouras. The company’s patented XV Technology® continues to enhance the diagnosis and treatment of respiratory conditions through advanced imaging software. Recently, 4DMedical expanded its capabilities in artificial intelligence medical imaging by acquiring Imbio, which specializes in lung and cardiothoracic diseases.
For further insights into AU:4DX stock, check out TipRanks’ Stock Analysis page.
